24
Participants
Start Date
March 7, 2022
Primary Completion Date
April 21, 2024
Study Completion Date
April 21, 2024
Dexmedetomidine
Dexmedetomidine is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and when compared to γ-aminobutyric acid receptor agonists like benzodiazepines, reduces delirium.
Placebo
Normal saline placebo will be given as continuous infusion.
Monash Medical Centre - Monash Health, Melbourne
King Abdulaziz Medical City - Riyadh, Riyadh
St. Joseph's Healthcare Hamilton, Hamilton
St. Joseph's Healthcare Hamilton
OTHER